Expanded indication development creating treatment — retinal gene therapy expanding beyond RPE65 mutation toward diverse retinal dystrophies (ABCA4, USH2A, choroideremia) enabling treatment of broader patient populations with inherited blindness, with the Retinal Gene Therapy Market positioned for expansion where therapeutic diversification enables broader vision restoration....